Citation index
John P.H. Wilding, DM
University of Liverpool, Institute of Life Course and Medical Sciences
Clinical endocrinologist and obesity researcher who led the STEP-1 pivotal trial of semaglutide 2.4 mg and has published extensively on pharmacological treatments for obesity.
Public profiles
Cited on Peptides Research Hub
- Semaglutide: research, pharmacology, and clinical evidence
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated cardiovascular risk reduction in people with obesity but without diabetes. This pillar covers mechanism, half-life, pharmacokinetics, pivotal trials, safety, and regulatory status.
- Semaglutide Safety Profile and Adverse Events
Semaglutide
This article summarizes adverse events from semaglutide's pivotal programs, the boxed warning for thyroid C-cell tumors, gastrointestinal event frequencies, pancreatitis, gallbladder disease, the retinopathy worsening signal from SUSTAIN-6, post-marketing suicidal ideation review, and considerations in pregnancy and lactation.